Follow @TMFMassimo
Recent articles
Sanofi and Regeneron's Latest Partnership
Max Macaluso | May 15, 2013
Late-stage clinical trials begin for this duo's experimental rheumatoid arthritis drug.
What Does This Failure Mean for Eli Lilly Investors?
Max Macaluso | May 13, 2013
Eli Lilly announced that it will stop developing cancer drug candidate enzastaurin. What does this mean for its business?
4 Technologies That Can Help Track Weight Loss
Max Macaluso | May 12, 2013
Apps and devices that help patients being treated for obesity track their progress.
This Week in Health Care
Max Macaluso and Dave Williamson | May 10, 2013
For the week ended May 10, 2013.
Why NPS Pharmaceuticals Is Up After Earnings
Max Macaluso | May 9, 2013
Orphan drugmaker NPS Pharmaceuticals reveals the progress of its Gattex launch.
3 Key Takeaways From Keryx's Earnings Report
Max Macaluso | May 8, 2013
What should investors focus on after this biotech's Q1 report?
Is Orexigen Therapeutics Burning Too Much Cash?
Max Macaluso | May 7, 2013
What is this biotech's burn rate?
This Week in Health Care
Max Macaluso and Dave Williamson | May 7, 2013
For the week ended May 3, 2013.
Hot Off the Press: Arena Pharmaceuticals’ First Quarter Results
Max Macaluso | May 2, 2013
Initial takeaways from Arena's Q1 report.
Is a Pharmaceutical Company the Same as a Biotech?
Max Macaluso | Apr 26, 2013
Have they become the same, or do they have different approaches to drug discovery?
Teva's 3 Biggest Challenges
Max Macaluso | Apr 26, 2013
Teva is one of the largest pharmaceutical companies in the world, but what roadblocks lie ahead?
1 Simple Way to Be a Better Investor
Max Macaluso | Apr 25, 2013
Trying to weight the pros and cons of a potential investment? SWOT away your worries and try this approach.
2 Upcoming Catalysts for Amarin
Max Macaluso | Apr 24, 2013
Two important events that Amarin investors need to watch.
Why This Obesity Drugmaker's Prescription Data Tells Only Half the Story
Max Macaluso | Apr 22, 2013
Vivus released prescription data for its obesity drug Qsymia last week, but its earnings report is more important.
This Week in Health Care
Max Macaluso and Dave Williamson | Apr 22, 2013
The Motley Fool's weekly health care show.
Obesity and Weight Management: How Much Weight Loss is Actually Necessary?
Max Macaluso | Apr 18, 2013
Obesity is a serious disease, but 5%-10% of weight loss may be enough to make a dramatic impact on a patient's health.
2 Things Regeneron Investors Need to Watch
Max Macaluso and Dave Williamson | Apr 18, 2013
Which issues should Regeneron investors focus on today?
How Allergy Season Taught Me an Important Investing Lesson
Max Macaluso | Apr 17, 2013
A look at how big pharma brands and markets its products.
This Week in Health Care
Max Macaluso and Dave Williamson | Apr 14, 2013
The Motley Fool's weekly health-care show.
Want to Retire Soon? Don't Invest in This Industry!
Max Macaluso and Sharon Yep | Apr 11, 2013
There are many different strategies investors can use to protect their wealth as they near retirement --- but investing in this industry is a risk that may not be worth taking.